A carregar...
Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
BACKGROUND: PARP inhibitors, such as Olaparib, have advanced the treatment of ovarian cancer by providing patients with an effective and molecularly-targeted maintenance therapy. However, all orally-administered drugs, including Olaparib, must undergo first-pass metabolism. In contrast, a nanopartic...
Na minha lista:
| Publicado no: | Int J Nanomedicine |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6278886/ https://ncbi.nlm.nih.gov/pubmed/30555227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S186881 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|